Production (Stage)
Altamira Therapeutics Ltd.
CYTOF
$0.10
$0.00060.60%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 107.89% | 117.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 107.89% | 117.97% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 41.84% | 400.10% | 37.28% | -15.30% | -38.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 8.53% | -112.69% | -118.84% | -163.77% | -529.27% |
| Total Operating Expenses | 87.40% | 347.73% | 591.14% | 16.35% | -40.47% |
| Operating Income | -87.40% | -329.39% | -351.05% | -11.19% | 40.41% |
| Income Before Tax | -86.96% | -15.10% | 71.94% | 74.68% | 77.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -86.96% | -14.67% | 72.02% | 74.70% | 77.06% |
| Earnings from Discontinued Operations | -- | -- | -- | 0.00% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.27% | 58.04% | 82.76% | 80.58% | 78.74% |
| EBIT | -87.40% | -329.39% | -351.05% | -11.19% | 40.41% |
| EBITDA | -- | -- | -- | 45.52% | 39.92% |
| EPS Basic | 94.26% | 92.54% | 92.72% | 91.53% | 90.79% |
| Normalized Basic EPS | 85.03% | -102.38% | -103.85% | 73.72% | 85.55% |
| EPS Diluted | 94.26% | 92.54% | 92.72% | 91.53% | 90.79% |
| Normalized Diluted EPS | 85.03% | -102.38% | -103.85% | 73.72% | 85.55% |
| Average Basic Shares Outstanding | 1,143.19% | 1,665.11% | 806.58% | 718.37% | 448.32% |
| Average Diluted Shares Outstanding | 910.36% | 1,116.37% | 847.86% | 780.59% | 574.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |